多囊卵巢综合征中妊娠期体重增加、食欲调节激素与二甲双胍治疗:一项纵向、安慰剂对照研究
该研究纳入多囊卵巢综合征(PCOS)孕妇接受二甲双胍(PCOS-M,n=36)或安慰剂(PCOS-P,n=37)治疗,以及健康孕妇(HC,n=15),检测妊娠早、晚期食欲调节激素。总体妊娠期体重增加过度(eGWG)患病率为44%(38/86);PCOS-M组eGWG患病率低于PCOS-P组(28% vs 62%,OR=0.4,95%CI 0.2-0.8,P=0.005)。eGWG与瘦素抵抗增强及妊娠期别孕烷醇酮生理性升高减弱相关,二甲双胍改善瘦素敏感性。
要点
- 总体eGWG患病率为44%(38/86)。
- PCOS-M组eGWG患病率28% vs PCOS-P组62%(OR=0.4,95%CI 0.2-0.8,P=0.005)。
- eGWG者妊娠早、晚期游离瘦素指数更高(P<0.001),妊娠晚期别孕烷醇酮更低(P=0.003)。
核心结论
- eGWG与瘦素抵抗增强及妊娠期血清别孕烷醇酮生理性升高减弱相关。
- 二甲双胍降低PCOS孕妇eGWG风险并改善瘦素敏感性。
研究设计与样本
- PCOS孕妇为随机对照试验的子样本,健康孕妇为前瞻性队列,来自11家挪威、瑞典和冰岛医院。
- PCOS-M组n=36,PCOS-P组n=37,HC组n=15。
- 检测妊娠早期和晚期血清瘦素、胃饥饿素、别孕烷醇酮及可溶性瘦素受体(sOB-R)。
主要发现
- 总体eGWG患病率为44%(38/86)。
- eGWG者妊娠早、晚期游离瘦素指数(FLI)高于非eGWG者(P<0.001),妊娠晚期别孕烷醇酮水平低于非eGWG者(P=0.003)。
- PCOS-M组eGWG患病率低于PCOS-P组(28% vs 62%,OR=0.4,95%CI 0.2-0.8,P=0.005)。
- PCOS-M组FLI随妊娠下降(P=0.01),PCOS-P组和HC组无变化。
- 胃饥饿素和别孕烷醇酮水平在PCOS-M、PCOS-P和HC组间整个妊娠期相当。
关键数值与推荐
- eGWG依据美国医学研究所(IOM)指南相对于体重指数判定。
- FLI作为瘦素敏感性生物标志物。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore mechanisms that modulate gestational weight gain (GWG) in women with polycystic ovary syndrome (PCOS) and healthy controls. DESIGN: Sub-sample of randomised controlled trials (PCOS) combined with a prospective cohort (controls). SETTING: Eleven Norwegian, Swedish, and Icelandic hospitals. POPULATION: Pregnant women with PCOS treated with metformin (PCOS-M, n = 36) or placebo (PCOS-P, n = 37), and healthy pregnant women (HC, n = 15). METHODS: Serum levels of the appetite regulating hormones leptin, ghrelin, allopregnanolone, and soluble leptin receptor (sOB-R) were determined in the first and third trimesters. MAIN OUTCOME MEASURES: Excessive GWG (eGWG) relative to body mass index according to Institute of Medicine (IOM) guideline. Serum leptin/sOB-R ratio, or free-leptin-index (FLI), as biomarker of leptin sensitivity. Serum ghrelin and allopregnanolone levels. RESULTS: The overall prevalence of eGWG was 44% (38/86). Women with eGWG had higher first and third trimester FLI (P < 0.001), and lower third trimester allopregnanolone levels (P = 0.003) versus women with non-eGWG. The prevalence of eGWG was lower in PCOS-M versus PCOS-P (28% versus 62%, odds ratio = 0.4, 95% CI 0.2-0.8, P = 0.005). FLI decreased during pregnancy in PCOS-M (P = 0.01), but remained unaltered in PCOS-P and HC. Ghrelin and allopregnanolone levels were comparable in PCOS-M, PCOS-P and HC throughout pregnancy. CONCLUSION: Excessive GWG is associated with enhanced leptin resistance, and attenuated physiological increase in serum allopregnanolone levels during pregnancy. Metformin reduces the risk for eGWG and improves leptin sensitivity in pregnant women with PCOS. TWEETABLE ABSTRACT: Metformin counteracts excessive weight gain and leptin resistance in pregnant women with polycystic ovary syndrome.
引用
- Molin J, Vanky E, Løvvik TS, et al. Gestational weight gain, appetite regulating hormones, and metformin treatment in polycystic ovary syndrome: A longitudinal, placebo-controlled study. BJOG. 2021. PMID: 34865304. doi:10.1111/1471-0528.17042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。